These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

197 related items for PubMed ID: 10415048

  • 1. Protective immune responses induced by vaccination with an expression genomic library of Leishmania major.
    Piedrafita D, Xu D, Hunter D, Harrison RA, Liew FY.
    J Immunol; 1999 Aug 01; 163(3):1467-72. PubMed ID: 10415048
    [Abstract] [Full Text] [Related]

  • 2. Vaccination with a plasmid DNA cocktail encoding the nucleosomal histones of Leishmania confers protection against murine cutaneous leishmaniosis.
    Iborra S, Soto M, Carrión J, Alonso C, Requena JM.
    Vaccine; 2004 Sep 28; 22(29-30):3865-76. PubMed ID: 15364433
    [Abstract] [Full Text] [Related]

  • 3. Evaluation of DNA/DNA and prime-boost vaccination using LPG3 against Leishmania major infection in susceptible BALB/c mice and its antigenic properties in human leishmaniasis.
    Abdian N, Gholami E, Zahedifard F, Safaee N, Rafati S.
    Exp Parasitol; 2011 Mar 28; 127(3):627-36. PubMed ID: 21187087
    [Abstract] [Full Text] [Related]

  • 4. Immunization with the hybrid protein vaccine, consisting of Leishmania major cysteine proteinases Type I (CPB) and Type II (CPA), partially protects against leishmaniasis.
    Zadeh-Vakili A, Taheri T, Taslimi Y, Doustdari F, Salmanian AH, Rafati S.
    Vaccine; 2004 May 07; 22(15-16):1930-40. PubMed ID: 15121305
    [Abstract] [Full Text] [Related]

  • 5. Leishmania donovani p36(LACK) DNA vaccine is highly immunogenic but not protective against experimental visceral leishmaniasis.
    Melby PC, Yang J, Zhao W, Perez LE, Cheng J.
    Infect Immun; 2001 Aug 07; 69(8):4719-25. PubMed ID: 11447143
    [Abstract] [Full Text] [Related]

  • 6. Vaccination with the Leishmania infantum acidic ribosomal P0 protein plus CpG oligodeoxynucleotides induces protection against cutaneous leishmaniasis in C57BL/6 mice but does not prevent progressive disease in BALB/c mice.
    Iborra S, Carrión J, Anderson C, Alonso C, Sacks D, Soto M.
    Infect Immun; 2005 Sep 07; 73(9):5842-52. PubMed ID: 16113303
    [Abstract] [Full Text] [Related]

  • 7. Comparison of potential protection induced by three vaccination strategies (DNA/DNA, Protein/Protein and DNA/Protein) against Leishmania major infection using Signal Peptidase type I in BALB/c mice.
    Rafati S, Ghaemimanesh F, Zahedifard F.
    Vaccine; 2006 Apr 12; 24(16):3290-7. PubMed ID: 16481076
    [Abstract] [Full Text] [Related]

  • 8. Molecular cloning of a novel protein antigen of Leishmania major that elicits a potent immune response in experimental murine leishmaniasis.
    Webb JR, Kaufmann D, Campos-Neto A, Reed SG.
    J Immunol; 1996 Dec 01; 157(11):5034-41. PubMed ID: 8943412
    [Abstract] [Full Text] [Related]

  • 9. Leishmania major heat shock protein 70 (HSP70) is not protective in murine models of cutaneous leishmaniasis and stimulates strong humoral responses in cutaneous and visceral leishmaniasis patients.
    Rafati S, Gholami E, Hassani N, Ghaemimanesh F, Taslimi Y, Taheri T, Soong L.
    Vaccine; 2007 May 22; 25(21):4159-69. PubMed ID: 17395340
    [Abstract] [Full Text] [Related]

  • 10. Leishmania major: a clone with low virulence for BALB/c mice elicits a Th1 type response and protects against infection with a highly virulent clone.
    Li J, Nolan TJ, Farrell JP.
    Exp Parasitol; 1997 Sep 22; 87(1):47-57. PubMed ID: 9287957
    [Abstract] [Full Text] [Related]

  • 11. Transmission blocking vaccine studies in leishmaniasis: II. Effect of immunisation using Leishmania major derived 63 kilodalton glycoprotein, lipophosphoglycan and whole parasite antigens on the course of L. major infection in BALB/c mice.
    Tonui WK, Mbati PA, Anjili CO, Orago AS, Turco SJ, Githure JI, Koech DK.
    East Afr Med J; 2001 Feb 22; 78(2):90-2. PubMed ID: 11682953
    [Abstract] [Full Text] [Related]

  • 12. Oral immunization using live Lactococcus lactis co-expressing LACK and IL-12 protects BALB/c mice against Leishmania major infection.
    Hugentobler F, Di Roberto RB, Gillard J, Cousineau B.
    Vaccine; 2012 Aug 24; 30(39):5726-32. PubMed ID: 22814408
    [Abstract] [Full Text] [Related]

  • 13. Transitory or long-lasting immunity to Leishmania major infection: the result of immunogenicity and multicomponent properties of histone DNA vaccines.
    Carrión J, Folgueira C, Alonso C.
    Vaccine; 2008 Feb 26; 26(9):1155-65. PubMed ID: 18255202
    [Abstract] [Full Text] [Related]

  • 14. Cysteine proteinase type III is protective against Leishmania infantum infection in BALB/c mice and highly antigenic in visceral leishmaniasis individuals.
    Khoshgoo N, Zahedifard F, Azizi H, Taslimi Y, Alonso MJ, Rafati S.
    Vaccine; 2008 Oct 29; 26(46):5822-9. PubMed ID: 18804512
    [Abstract] [Full Text] [Related]

  • 15. Cross-protection against Leishmania donovani but not L. Braziliensis caused by vaccination with L. Major soluble promastigote exogenous antigens in BALB/c mice.
    Tonui WK, Titus RG.
    Am J Trop Med Hyg; 2007 Mar 29; 76(3):579-84. PubMed ID: 17360887
    [Abstract] [Full Text] [Related]

  • 16. [Immuno-modulating effects of eukaryotic expressing vectors of IL-12 and GM-CSF associated to DNA-based vaccination against experimental cutaneous leishmaniasis in BALB/c mouse].
    Ahmed SB, Dellagi K, Bahloul C.
    Arch Inst Pasteur Tunis; 2009 Mar 29; 86(1-4):39-50. PubMed ID: 20707219
    [Abstract] [Full Text] [Related]

  • 17. Induction of a Th1 immune response and simultaneous lack of activation of a Th2 response are required for generation of immunity to leishmaniasis.
    Sjölander A, Baldwin TM, Curtis JM, Handman E.
    J Immunol; 1998 Apr 15; 160(8):3949-57. PubMed ID: 9558102
    [Abstract] [Full Text] [Related]

  • 18. A comparative evaluation of different DNA vaccine candidates against experimental murine leishmaniasis due to L. major.
    Ahmed SB, Bahloul C, Robbana C, Askri S, Dellagi K.
    Vaccine; 2004 Apr 16; 22(13-14):1631-9. PubMed ID: 15068845
    [Abstract] [Full Text] [Related]

  • 19. Effect of IL-22 on DNA vaccine encoding LACK gene of Leishmania major in BALB/c mice.
    Hezarjaribi HZ, Ghaffarifar F, Dalimi A, Sharifi Z, Jorjani O.
    Exp Parasitol; 2013 Jul 16; 134(3):341-8. PubMed ID: 23541883
    [Abstract] [Full Text] [Related]

  • 20. Leishmania major MAP kinase 10 is protective against experimental L. major infection.
    Kumari S, Singh S, Saha B, Paliwal PK.
    Vaccine; 2011 Nov 08; 29(48):8783-7. PubMed ID: 21527301
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 10.